Low doses of oral dexamethasone for hormone-refractory prostate carcinoma

Cancer

Volumn 89, Issue 12, 2000, Pages 2570-2576

  Nishimura, Kazuo ^a   Nonomura, Norio ^b   Yasunaga, Yutaka ^b   Takaha, Natsuki ^b   Inoue, Hitoshi ^b   Sugao, Hideki ^c   Yamaguchi, Seiji ^c   Ukimura, Osanu ^c   Miki, Tsuneharu ^d   Okuyama, Akihiko ^e  

^a OSAKA UNIVERSITY   (Japan)

^b OSAKA ROSAI HOSPITAL   (Japan)

^c Mino Municipal Hospital   (Japan)

^d IKEDA MUNICIPAL HOSPITAL   (Japan)

^e KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

Dexamethasone; Hormone refractory; Prostate carcinoma; Prostate specific antigen

Indexed keywords

DEXAMETHASONE; HEMOGLOBIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANALGESIA; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; HEMOGLOBIN DETERMINATION; HUMAN; LONG TERM CARE; MALE; PRIORITY JOURNAL; PROSTATE CARCINOMA; SURVIVAL RATE; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS; CATARACT; DEXAMETHASONE; DIABETES MELLITUS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; HYPERTENSION; MALE; MENTAL DISORDERS; MIDDLE AGED; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0034672087     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20001215)89:12<2570::AID-CNCR9>3.0.CO;2-H     Document Type: Article

References (23)

1. Cancer statistics, 1998
2. A controlled trial of leuprolide with and without flutamide in prostate carcinoma
3. Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
4. Hydrocortisone with or without mitoxantrone in men with hormone-refractory prostate cancer: Results of the cancer and leukemia group B 9182 study
5. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative endpoints
6. Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm
7. Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer
8. Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer
9. Prostate specific antigen level and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma
10. Treatment of metastatic prostate cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response
11. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the Prostate-Specific Antigen Working Group
12. Glucocorticoid in cancer therapy
13. The use of glucocorticoid in acute lymphoblastic leukemia of childhood: Molecular, cellular and clinical considerations
14. Glucocorticoid-induced long-term remission in primary cerebral lymphoma: Case report and review of the literature
15. Mediation of glucocorticoid receptor function by transforming growth factor beta I expression in human PC-3 prostate cancer cells
16. Homologous down regulation of the glucocorticoid receptor: The molecular machinery
17. Differences in down-regulation of glucocorticoid receptor mRNA by cortisol, prednisone and dexamethasone in HeLa cells
18. The assessment of treatment outcomes in metastatic prostate cancer: Changing endpoints
19. Trimetrexate in prostatic cancer: Preliminary observations on the use of prostate-specific antigen and acid phosphatase as a marker in measurable hormone-refractory disease
20. Apples and oranges: Building a consensus for standardized eligibility criteria and end points in prostate cancer clinical trials
21. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer
22. Change in serum prostate-specific antigen as a marker of response to cytotoxic therapy for hormone-refractory prostate cancer
23. Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer